Alnylam Pharmaceuticals, Inc., a Cambridge-based RNAi therapeutics company, announced Monday that it has earned a development milestone payment from GlaxoSmithKline totaling $3.2 million.
The milestone payment is related to progress in the companies’ collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine. Alnylam’s VaxiRNA platform uses RNAi technology for the enhanced manufacturing of vaccine products.
“We have made important progress with GSK in advancing Alnylam’s VaxiRNA technology, and are pleased to have achieved a key milestone in our collaborative effort,” said Rachel Meyers, vice president, research and RNAi lead development.
D.C. Denison can be reached at firstname.lastname@example.org.